Business Description

Biocept Inc logo
Biocept Inc
NAICS : 621511 SIC : 8731
ISIN : US09072V4023
Description
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Financial Strength

Name Current Vs Industry Vs History

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History

Dividend & Buy Back

Name Current Vs Industry Vs History

Profitability Rank

Name Current Vs Industry Vs History
FCF Margin %
-1311.45
OCF Margin %
-1261.52
Name Current Vs Industry Vs History
EV-to-Forward-Revenue
0.94

Financials (Next Earnings Date:2026-07-14 Est.)

STU:B00's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Biocept Inc Executives

Details

GF Valueâ„¢

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 1.328
EPS (TTM) (€) -49.041
Beta -
3-Year Sharpe Ratio -34.93
3-Year Sortino Ratio -3.45
Volatility % -
14-Day RSI -
14-Day ATR (€) -
20-Day SMA (€) 6.42
12-1 Month Momentum % -
52-Week Range (€) 6.42 - 6.42
Shares Outstanding (Mil) 2.63

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 0
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biocept Inc Filings

Filing Date Document Date Form
No Filing Data

Biocept Inc Stock Events

Financials Calendars
Event Date Price (€)
Third quarter earnings results for 2026 2026-10-19 In 101 days
Second quarter earnings results for 2026 2026-08-20 In 41 days
First quarter earnings results for 2026 2026-07-14 In 4 days
0.0333333:1 Stock Split 2023-05-17 6.42 (+0.00%)
0.1:1 Stock Split 2020-09-08 135.00 (+18.20%)
0.033333:1 Stock Split 2018-07-10 1,071.01 (-11.19%)
0.333333:1 Stock Split 2016-09-29 --
Show
Entries

Biocept Inc Frequently Asked Questions

What is Biocept Inc(STU:B00)'s stock price today?
The current price of STU:B00 is €6.42. The 52 week high of STU:B00 is €6.42 and 52 week low is €6.42.
When is next earnings date of Biocept Inc(STU:B00)?
The next earnings date of Biocept Inc(STU:B00) is 2026-07-14 Est..
Does Biocept Inc(STU:B00) pay dividends? If so, how much?
Biocept Inc(STU:B00) does not pay dividend.

Articles on Biocept Inc

No articles.